Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, Armando Santoro, Amitkumar Mehta, Paul M Barr, Neha Mehta-Shah, Graham P Collins, Stephen M Ansell, Joshua D Brody, Eva Domingo-Domenech, Nathalie A Johnson, David Cunningham, Silvia Ferrari, Julie Lisano, Jennifer Krajewski, Rachael Wen, Alev Akyol, Russell Crowe, Kerry J Savage
Author Information
- Pier Luigi Zinzani: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," University of Bologna, Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. ORCID
- Gilles Salles: Memorial Sloan Kettering Cancer Center, New York, NY. ORCID
- Alison J Moskowitz: Memorial Sloan Kettering Cancer Center, New York, NY.
- Armando Santoro: Humanitas University, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. ORCID
- Amitkumar Mehta: School of Medicine, University of Alabama at Birmingham, Birmingham, AL. ORCID
- Paul M Barr: Department of Medicine, University of Rochester, Rochester, NY. ORCID
- Neha Mehta-Shah: Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO. ORCID
- Graham P Collins: Department of Hematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, United Kingdom.
- Stephen M Ansell: Division of Hematology, Mayo Clinic, Rochester, MN.
- Joshua D Brody: Icahn School of Medicine at Mount Sinai, New York, NY. ORCID
- Eva Domingo-Domenech: Clinical Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. ORCID
- Nathalie A Johnson: Department of Medicine & Oncology, Jewish General Hospital, Montreal, QC, Canada.
- David Cunningham: Royal Marsden Hospital, London, United Kingdom. ORCID
- Silvia Ferrari: Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. ORCID
- Julie Lisano: Seagen Inc, Bothell, WA.
- Jennifer Krajewski: Bristol Myers Squibb, Princeton, NJ.
- Rachael Wen: Bristol Myers Squibb, Princeton, NJ.
- Alev Akyol: Bristol Myers Squibb, Princeton, NJ.
- Russell Crowe: Bristol Myers Squibb, Princeton, NJ.
- Kerry J Savage: BC Cancer, Vancouver, BC, Canada. ORCID
No abstract text available.
- Blood. 2014 Nov 6;124(19):2983-6
[PMID: 25224410]
- Front Oncol. 2022 Jun 07;12:884091
[PMID: 35747818]
- J Clin Oncol. 2016 Aug 10;34(23):2698-704
[PMID: 27269947]
- Blood. 2014 May 15;123(20):3095-100
[PMID: 24652992]
- J Clin Oncol. 2019 Nov 20;37(33):3081-3089
[PMID: 31398081]
- Blood. 2018 Mar 15;131(11):1183-1194
[PMID: 29229594]
- J Clin Oncol. 2012 Jun 20;30(18):2190-6
[PMID: 22614995]
- J Clin Oncol. 2020 Jan 1;38(1):20-28
[PMID: 31532724]
- J Clin Oncol. 2011 Jun 20;29(18):2598-607
[PMID: 21576639]
- Eur J Cancer. 2021 May;148:411-421
[PMID: 33794441]
- Blood. 2012 Feb 16;119(7):1643-9
[PMID: 22160616]
- Ann Oncol. 2022 Mar;33(3):288-298
[PMID: 34921960]
- J Immunother Cancer. 2022 Jun;10(6):
[PMID: 35750419]
- Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3
[PMID: 31029646]
- Blood Adv. 2021 Dec 14;5(23):5098-5106
[PMID: 34507350]
- Blood. 2009 Sep 3;114(10):2149-58
[PMID: 19597183]
- J Clin Oncol. 2013 Jun 1;31(16):1970-6
[PMID: 23610113]
- J Clin Oncol. 2019 Aug 10;37(23):1997-2007
[PMID: 31112476]
- J Clin Oncol. 2014 Sep 20;32(27):3059-68
[PMID: 25113753]
- P30 CA008748/NCI NIH HHS
Humans
Brentuximab Vedotin
Lymphoma, T-Cell, Peripheral
Nivolumab
Lymphoma, T-Cell, Cutaneous
Male
Middle Aged
Female
Antineoplastic Combined Chemotherapy Protocols
Aged
Neoplasm Recurrence, Local
Adult
Skin Neoplasms
